Vergo Pharma Research Laboratories Private Limited Pharmaceutical Export Profile — India (DGFT 2022–2026)

Name: Vergo Pharma Research Laboratories Private Limited Pharmaceutical Export Portfolio Dataset — 5 Products, $2.1M FOB USD, India (DGFT 2022–2026)
Creator: TransData Nexus

Suresh Sormare

Explore

Vergo Pharma Research Laboratories Private Limited — Pharmaceutical Exporter Profile (2026) | 5 Products, $2.1M Trade | TransData Nexus

Vergo Pharma Research Laboratories Private Limited

Indian Pharmaceutical Exporter · Antibiotics Specialist · $2.1M Total Trade · DGFT Verified

Vergo Pharma Research Laboratories Private Limited is an Indian pharmaceutical exporter with a total trade value of $2.1M across 5 products in 5 therapeutic categories. Based on 162 verified export shipments from Indian Customs (DGFT) records, the company actively competes across multiple product segments. Top exports include Clindamycin ($955.0K), Colchicine ($480.4K), Pravastatin ($271.5K).

Vergo Pharma Research Laboratories Private Limited — Export Portfolio & Destination Treemap

Vergo Pharma Research Laboratories Private Limited pharmaceutical export portfolio — 5 products across 5 therapeutic categories. Source: Indian Customs (DGFT).

Who is Vergo Pharma Research Laboratories Private Limited? — Company Overview & Market Position

Vergo Pharma Research Laboratories Private Limited, incorporated on August 10, 2010, is a private, non-government company based in Panaji, Goa, India. The company is registered with the Corporate Identification Number (CIN) U73200GA2010PTC006462. Its authorized and paid-up capital stands at ₹27.01 crore (approximately $3.6 million USD). The registered office is located at Keni Building, Dr. Dada Vaidya Road, Panaji, Goa, India, 403001.

Vergo Pharma specializes in the research and development of pharmaceutical formulations, focusing on generic drugs. The company offers a comprehensive suite of services, including formulation development, contract manufacturing, and clinical bioavailability/bioequivalence (BA/BE) studies. These services cater to global clients and partners, particularly in regulated markets. As of March 2026, Vergo Pharma employs over 200 professionals, including scientists, researchers, and support staff.

What Does Vergo Pharma Research Laboratories Private Limited Export? — Product Portfolio Analysis

Top Products by Export Value

1Clindamycin$955.0K 2

Product Portfolio — Top 5 by Export Value

Vergo Pharma Research Laboratories Private Limited exports 5 pharmaceutical products across 5 therapeutic categories.

#	Product	Category	Export Value	Shipments	Market Share	Rank
1	Clindamycin	Antibiotics	$955.0K	82	1.1%	14
2	Colchicine	Lipid & Metabolism	$480.4K	47	2.3%	9
3	Pravastatin	Cardiovascular	$271.5K	15	0.9%	8
4	Ethambutol	Tuberculosis Medications	$211.2K	11	0.0%	11
5	Dapsone	Antimalarial & Antiparasitic	$149.8K	7	0.7%	10

Vergo Pharma Research Laboratories Private Limited exports 5 pharmaceutical products across 5 therapeutic categories with a total export value of $2.1M. The top category is Antibiotics (46.2% of portfolio), followed by Lipid & Metabolism (23.2%), indicating a concentrated portfolio with the top 5 products accounting for 100.0% of total export value.

Vergo Pharma Research Laboratories Private Limited — Corporate Profile & Information

Headquarters, ownership, manufacturing facilities, and key leadership

1Corporate Overview

2Manufacturing Facilities

Vergo Pharma operates a cGMP-compliant manufacturing facility located in the Verna Industrial Estate, Goa, India. This facility specializes in the production of oral solid dosage forms, such as tablets and capsules, and has a manufacturing capacity of approximately 500 million tablets per annum. The plant is approved by regulatory bodies including the UK's MHRA, the World Health Organization (WHO), and the Therapeutic Goods Administration (TGA) of Australia.

3Key Leadership

The leadership team at Vergo Pharma comprises experienced professionals with diverse expertise in the pharmaceutical industry. Prasad Vassudev Keni serves as the Managing Director, overseeing the company's strategic direction and operations. Vini Prasad Keni holds the position of Director, contributing to the company's governance and decision-making processes. Kashyap Prasad Keni, also a Director, leads business development initiatives, focusing on expanding the company's market presence. Amol Shivaji Borkar serves as the Chief Financial Officer, managing financial operations and ensuring fiscal responsibility.

TransData Nexus Research · Government registries, company filings, regulatory databasesMar 2026

Where Does Vergo Pharma Research Laboratories Private Limited Export? — Destination Intelligence

Regulated market presence, emerging market penetration, and geographic strategy

1Regulated Markets

Vergo Pharma has established a presence in several regulated markets, including the United States, European Union, United Kingdom, and Australia. The company's manufacturing facility in Goa holds approvals from the UK's MHRA, WHO, and TGA Australia, facilitating market access in these regions. Additionally, Vergo Pharma has commercialized 12 products for the UK market, demonstrating its capability to meet stringent regulatory standards.

2Emerging Markets

Vergo Pharma has expanded its reach into emerging markets across Africa, Latin America, and Southeast Asia. The company's adherence to international quality standards, as evidenced by its WHO prequalification and EU GMP certifications, enhances its ability to penetrate these markets. These certifications enable Vergo Pharma to supply products to countries that recognize WHO prequalified manufacturers, thereby broadening its global footprint.

3Geographic Strategy

Vergo Pharma's geographic strategy involves a balanced approach, targeting both regulated and emerging markets to diversify its revenue streams. The company's focus on obtaining approvals from regulatory bodies such as the MHRA, WHO, and TGA Australia underscores its commitment to quality and compliance, which is crucial for accessing regulated markets. Simultaneously, Vergo Pharma's WHO prequalification and EU GMP certifications position it favorably to serve emerging markets, mitigating concentration risk and enhancing its strategic direction.

Vergo Pharma Research Laboratories Private Limited — Manufacturing & Regulatory Profile

FDA status, WHO-GMP certification, EU GMP compliance, and regulatory track record

1FDA Status

As of March 2026, Vergo Pharma's manufacturing facility in Goa is not registered with the U.S. Food and Drug Administration (FDA). The company has not filed any Abbreviated New Drug Applications (ANDAs) or Drug Master Files (DMFs) with the FDA, and there is no available information regarding FDA inspections or observations. This indicates that Vergo Pharma currently does not supply pharmaceutical products to the U.S. market.

2WHO & EU GMP

Vergo Pharma's manufacturing facility holds certifications from the World Health Organization (WHO) and the European Union Good Manufacturing Practice (EU GMP). These certifications validate the company's adherence to international quality standards, enabling it to supply pharmaceutical products to markets that recognize WHO prequalified manufacturers and EU GMP-compliant facilities.

3CDSCO & Indian Regulatory

Vergo Pharma's manufacturing facility in Goa is approved by the Central Drugs Standard Control Organisation (CDSCO), the national regulatory authority in India. The facility holds a valid manufacturing license issued by the CDSCO, ensuring compliance with Indian pharmaceutical regulations. Additionally, the company has obtained export No Objection Certificates (NOCs) from the Directorate General of Foreign Trade (DGFT), authorizing it to export pharmaceutical products to various international markets.

Vergo Pharma Research Laboratories Private Limited — Competitive Positioning Among Indian Pharma Exporters

Market share comparison, key differentiators, and strategic analysis

1Competitive Landscape

In the generic pharmaceutical sector, Vergo Pharma faces competition from both domestic and international companies. Key competitors include established Indian pharmaceutical firms with extensive product portfolios and global distribution networks. Vergo Pharma differentiates itself through its specialized services, including formulation development, contract manufacturing, and clinical BA/BE studies, catering to both regulated and emerging markets. The company's certifications from WHO and EU GMP further enhance its competitive position by ensuring product quality and regulatory compliance.

2Key Differentiators

Vergo Pharma's key differentiators include its integrated approach as a Contract Development and Manufacturing Organization (CDMO) and Contract Research Organization (CRO), offering a comprehensive suite of services from formulation development to clinical studies. The company's cGMP-compliant manufacturing facility, approved by international regulatory bodies, underscores its commitment to quality. Additionally, Vergo Pharma's focus on both regulated and emerging markets allows it to leverage a diverse customer base, mitigating risks associated with market concentration.

3Strategic Position

Buyer Due Diligence Brief — Evaluating Vergo Pharma Research Laboratories Private Limited as a Supplier

Track record assessment, certifications to verify, and pre-order checks

1Supplier Assessment

Vergo Pharma has demonstrated a consistent track record in pharmaceutical manufacturing, with a total export value of $2.1 million USD across 162 shipments from 2022 to 2026. The company's portfolio includes five products across five therapeutic categories, with the top five products accounting for 100% of its export value. This indicates a focused product strategy, which may offer advantages in quality control and operational efficiency. The company's adherence to international quality standards, as evidenced by its WHO prequalification and EU GMP certifications, further underscores its reliability as a supplier.

2Certifications to Verify

Importers should verify the following certifications when considering Vergo Pharma as a supplier:

WHO Prequalification: Confirms that the company's products meet international quality standards recognized by the World Health Organization. Verification can be done through the WHO's official website or by contacting the company directly.

EU GMP Certification: Indicates compliance with European Union Good Manufacturing Practice standards. This certification can be verified through the European Medicines Agency (EMA) or by contacting Vergo Pharma.

Frequently Asked Questions — Vergo Pharma Research Laboratories Private Limited

How many pharmaceutical products does Vergo Pharma Research Laboratories Private Limited export from India?

Vergo Pharma Research Laboratories Private Limited exports 5 pharmaceutical products across 5 therapeutic categories. The top exports are Clindamycin ($955.0K), Colchicine ($480.4K), Pravastatin ($271.5K), Ethambutol ($211.2K), Dapsone ($149.8K). Total export value is $2.1M.

What is Vergo Pharma Research Laboratories Private Limited's total pharmaceutical export value?

Vergo Pharma Research Laboratories Private Limited's total pharmaceutical export value is $2.1M, based on 162 verified shipments recorded in Indian Customs (DGFT) data.

What therapeutic categories does Vergo Pharma Research Laboratories Private Limited cover?

Vergo Pharma Research Laboratories Private Limited exports across 5 therapeutic categories. The largest are Antibiotics (46.2%, 1 products), Lipid & Metabolism (23.2%, 1 products), Cardiovascular (13.1%, 1 products).

Get Full Vergo Pharma Research Laboratories Private Limited Export Intelligence

Access shipment-level details, pricing data, buyer connections, product breakdown, and competitive analysis. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.

Contact for Data Access Request Live Demo

Official References & Regulatory Resources

Verify manufacturer licensing, GMP certification, and export registration with the agencies above.

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Data Source & Methodology

Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. Market share calculated relative to total Indian pharmaceutical exports per product category. For current shipment-level data, contact TransData Nexus.